Identification of patients with chronic obstructive pulmonary disease (COPD) by measurement of plasma biomarkers

Introduction:  Inflammation is an important constituent of the pathology of chronic obstructive pulmonary disease (COPD), leading to alveolar destruction and airway remodelling.

[1]  N. Chavannes,et al.  Local and systemic inflammation in patients with chronic obstructive pulmonary disease: soluble tumor necrosis factor receptors are increased in sputum. , 2002, American journal of respiratory and critical care medicine.

[2]  J. Roca,et al.  Standardization of the measurement of transfer factor (diffusing capacity). Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. , 1993, The European respiratory journal. Supplement.

[3]  R. Crystal,et al.  Cigarette smoking and lung destruction. Accumulation of neutrophils in the lungs of cigarette smokers. , 1983, The American review of respiratory disease.

[4]  A. Schols,et al.  Systemic effects in COPD. , 2002, Chest.

[5]  B. Stoel,et al.  α1-Antitrypsin deficiency · 7: Computed tomographic imaging in α1-antitrypsin deficiency , 2004, Thorax.

[6]  W. MacNee,et al.  Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper , 2004, European Respiratory Journal.

[7]  S. Anderson,et al.  Airway responsiveness : standardized challenge testing with pharmacological, physical and sensitizing stimuli in adults , 1993 .

[8]  D. Niewoehner,et al.  Pathologic changes in the peripheral airways of young cigarette smokers. , 1974, The New England journal of medicine.

[9]  J. Bousquet,et al.  Sputum metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio correlates with airflow obstruction in asthma and chronic bronchitis. , 1998, American journal of respiratory and critical care medicine.

[10]  D. Postma,et al.  Chronic obstructive pulmonary disease. , 2002, Clinical evidence.

[11]  J. Mege,et al.  Tumor necrosis factor-alpha levels and weight loss in chronic obstructive pulmonary disease. , 1994, American journal of respiratory and critical care medicine.

[12]  W. MacNee,et al.  Quantifying Emphysema by CT Scanning , 1991 .

[13]  P. Barnes,et al.  Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. , 1996, American journal of respiratory and critical care medicine.

[14]  S. Hurd,et al.  Global Strategy for the Diagnosis, Management and Prevention of COPD: 2003 update , 2003, European Respiratory Journal.

[15]  S. Kudoh,et al.  Clinical significance of serum concentration of interleukin 8 in patients with bronchial asthma or chronic pulmonary emphysema. , 1996, Respiration; international review of thoracic diseases.

[16]  J. Roca,et al.  Standardization of the measurement of transfer factor (diffusing capacity) , 1993, European Respiratory Journal.

[17]  R. Senior,et al.  Matrix metalloproteinase-9 in lung remodeling. , 2003, American journal of respiratory cell and molecular biology.

[18]  J. Cavaillon,et al.  Variable estimates of cytokine levels produced by commercial ELISA kits: results using international cytokine standards. , 1995, Journal of immunological methods.

[19]  Jan Stolk,et al.  Optimization and Standardization of Lung Densitometry in the Assessment of Pulmonary Emphysema , 2004, Investigative radiology.

[20]  R. Stockley.  Neutrophils and protease/antiprotease imbalance. , 1999, American journal of respiratory and critical care medicine.

[21]  P. Paré,et al.  The diagnosis of emphysema. A computed tomographic-pathologic correlation. , 1986, The American review of respiratory disease.

[22]  J E Cotes,et al.  Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. , 1993, The European respiratory journal. Supplement.

[23]  P. Barnes,et al.  Granulocyte activation markers in induced sputum: comparison between chronic obstructive pulmonary disease, asthma, and normal subjects. , 1997, American journal of respiratory and critical care medicine.

[24]  J E Cotes,et al.  Lung volumes and forced ventilatory flows , 1993, European Respiratory Journal.

[25]  L. O’Driscoll,et al.  Matrix metalloproteinase expression and production by alveolar macrophages in emphysema. , 1997, American journal of respiratory and critical care medicine.

[26]  D. Sin,et al.  The risk of osteoporosis in Caucasian men and women with obstructive airways disease. , 2003, The American journal of medicine.

[27]  C. O'connor,et al.  Elevated levels of matrix metalloproteinases in bronchoalveolar lavage fluid of emphysematous patients. , 1997, Thorax.

[28]  E. Wouters,et al.  Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease. , 1996, Thorax.

[29]  M. Wadhwa,et al.  Cytokine immunoassays: recommendations for standardisation, calibration and validation. , 1998, Journal of immunological methods.

[30]  B. Balbi,et al.  Increased MCP-1 and MIP-1b in bronchoalveolar lavage fluid of chronic bronchitics , 1999 .

[31]  W. D. de Boer,et al.  Cytokines and therapy in COPD: a promising combination? , 2002, Chest.

[32]  D. Romberger,et al.  Cigarette smoke induces interleukin-8 release from human bronchial epithelial cells. , 1997, American journal of respiratory and critical care medicine.

[33]  L. Kunz-Schughart,et al.  Expression and Release of Interleukin-8 by Human Bronchial Epithelial Cells from Patients with Chronic Obstructive Pulmonary Disease, Smokers, and Never-Smokers , 2003, Respiration.

[34]  K. Chung,et al.  Cytokines in chronic obstructive pulmonary disease , 2001, European Respiratory Journal.

[35]  P. Barnes,et al.  Release and activity of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 by alveolar macrophages from patients with chronic obstructive pulmonary disease. , 2002, American journal of respiratory cell and molecular biology.

[36]  K. Chung,et al.  Balance of matrix metalloprotease-9 and tissue inhibitor of metalloprotease-1 from alveolar macrophages in cigarette smokers. Regulation by interleukin-10. , 2000, American journal of respiratory and critical care medicine.

[37]  P. Barnes,et al.  Increased levels of the chemokines GROα and MCP-1 in sputum samples from patients with COPD , 2002, Thorax.

[38]  S. Rennard,et al.  Pathogenesis of COPD. , 2003, Clinical cornerstone.

[39]  Hunninghake Gw,et al.  Cigarette smoking and lung destruction: accumulation of neutrophils in the lungs of cigarette smokers , 1983 .

[40]  N. Müller,et al.  "Density mask". An objective method to quantitate emphysema using computed tomography. , 1988, Chest.

[41]  W. D. Boer.  Cytokines and therapy in COPD: A promising combination? , 2002 .

[42]  W. MacNee,et al.  Quantifying emphysema by CT scanning. Clinicopathologic correlates. , 1991, Annals of the New York Academy of Sciences.

[43]  P. Jeffery,et al.  Structural and inflammatory changes in COPD: a comparison with asthma. , 1998, Thorax.

[44]  R. Pauwels,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. , 2001, American journal of respiratory and critical care medicine.